# Cancer Prevention & Control

> **NIH NIH P30** · GEORGETOWN UNIVERSITY · 2024 · $15,545

## Abstract

CANCER PREVENTION AND CONTROL PROGRAM: PROJECT SUMMARY
The scientific goals of the Cancer Prevention and Control Program (CPC) are to help alleviate the burden of
cancer by elucidating the biobehavioral underpinnings of cancer risk and response, motivating lifestyle and
associated changes, and informing cancer care delivery and policy. Research falls under three integrated
Specific Aims: (1) identifying risks associated with cancer causation and progression; (2) intervening to improve
cancer outcomes and promote survivorship; and (3) conducting health services research to advise cancer
practice and policy. This programmatic work addresses molecular and social determinants of health, and
eradicates disparities and cancers highly prevalent within the Catchment Area, including screening-eligible
cancers. CPC is co-led by Lisa Carter-Bawa, PhD, APRN, Laura Rozek, PhD, and Kenneth Tercyak, PhD, with
complementary expertise in clinical science, molecular epidemiology, and health behaviors and outcomes. The
recruitment of Carter-Bawa and Rozek to CPC's leadership structure provides additional depth and strength in
translating interventions to populations, and new opportunities for inter-programmatic partnerships with basic
and clinical scientists. CPC includes 33 Members across 10 departments: 17 of these Members (52%) were
recruited (13 strategically with 12 external, 1 internal) to the Program in the current cycle, with attention to gender,
racial, and ethnic diversity. During the reporting period, CPC benefited from $17M+ in strategic investments to
extend its research portfolio. Georgetown University invested an additional $1M in physical space for the
Program in Washington, DC. Hackensack Meridian Health invested an additional $3M in 6,000 sq/ft of new
research space for the Program in Nutley, NJ. In April 2023, CPC holds $7.5M in cancer-focused, peer-reviewed
funding, of which $5.6M (75%) is from NCI, $1.4M (19%) is from other NIH sources, and $0.5M (6%) derives
from additional peer-reviewed agencies. CPC's total peer-reviewed funding is $7.5M (23% over 2018). Scientific
leadership roles this cycle include 17 multi-PI grants, an FDA/NIH center for tobacco regulatory science, two NCI
Cancer Intervention and Surveillance Modeling Network teams, a minority/underserved Community Oncology
Research Program grant, and six training-related grants (including a new NCI T32 in cancer population science)
that enrich the overall mission and climate of the cancer center. In the current project period, CPC authored 348
cancer-relevant publications, of which 118 (34%) were intra-programmatic, 52 (15%) were inter-programmatic,
and 12% were in high-impact (IF≥10) journals. CPC's influence has grown with the expansion of its leadership
structure across the LCCC cancer research Consortium, the recruitment of highly talented and diverse early-
stage and established faculty, a successful training program, and a substantial funding base. These
transformations are accele...

## Key facts

- **NIH application ID:** 10849006
- **Project number:** 2P30CA051008-30
- **Recipient organization:** GEORGETOWN UNIVERSITY
- **Principal Investigator:** LAURA ROZEK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $15,545
- **Award type:** 2
- **Project period:** 1997-08-15 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10849006

## Citation

> US National Institutes of Health, RePORTER application 10849006, Cancer Prevention & Control (2P30CA051008-30). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10849006. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*